Intravenous infusion of urokinase thrombolysis for acute cerebral infarction in 23 cases

Objective To evaluate the efficancy and safety of intravenous infusion of urokinase for patients with acute cerebral infarction.Methods Following neurological evaluation and computed tomography scan of the brain.23 patients with acute cerebral infarction were infused with high-dose urokinase, ranging from 10×105 IU to 20×105 IU, within 6 hours after the onset of symptoms.Neurological outcome, incidence of symptomatic or asymptomatic or asymptomatic intracranial hematoma, and systemic hemorrhage were evaluated at 2 hours, 24 hours, and 1 month after treatment.Results 12 patients had major neurological improvement and 7 had slight improvement at 2 hours after the initiation of urokinase, but 4 relapsed within 24 horus.When evaluated at 1 month after thrombolytic treatment, patients received urokinase within 4 hours after the onset had significantly better improvement of ESS than those received the medicine at 4-6 hours.Asvmptomatic hemorrhagic infarction only occurred in one patient.3 patients had mild gingival bleeding, but none died.Conclusion High-dose intravenous urokinase thrombolysis could become an effective and safe treatment for acute cerebral infarction within 6 hours after the onset of symptom.